Ethical Challenges with Left Ventricular Assist Devices as Destination Therapy
Author Information
Author(s): Aaron G. Rizzieri, Joseph L. Verheijde, Mohamed Y. Rady, Joan L. McGregor
Primary Institution: Arizona State University and Mayo Clinic
Hypothesis
What are the ethical challenges associated with using left ventricular assist devices (LVADs) as destination therapy for patients with chronic end-stage heart failure?
Conclusion
While LVADs can prolong survival in chronic end-stage heart failure patients, they may also negatively impact quality of life due to complications.
Supporting Evidence
- LVADs can improve survival rates compared to optimal medical management.
- Complications from LVADs can lead to a decline in quality of life.
- Caregivers of LVAD recipients may experience significant physical and psychological burdens.
Takeaway
Using a special heart pump can help some people live longer, but it can also make them feel worse because of infections and other problems.
Methodology
The study reviews survival data and complications from clinical trials involving LVADs as destination therapy.
Potential Biases
The study may be biased due to the lack of diverse participant demographics, particularly the underrepresentation of female patients.
Limitations
The preponderance of male patients in the REMATCH trial limits the generalizability of the findings to female patients.
Participant Demographics
The majority of participants in the REMATCH trial were male (82% in OMM and 78% in LVAD-DT).
Statistical Information
P-Value
0.002
Statistical Significance
p=0.002
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website